Combination PPAR and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2
Figure 5
Knock down of S100A2 blunts the antiproliferative effect of TZD and rexinoids in A375(DR) cells. A375(DRO), the SCR infected, and an shS100A2 infected subline were grown in 2% fetal bovine serum RPMI in the presence of 1 mol/L of LGD1069, TZD, or the combination for 6 days. Cell growth was analyzed using a nonradioactive cell proliferation assay. Proliferation was compared to that of cells grown in volume equivalent vehicle (DMSO—set at 100%). Proliferation was statistically significantly attenuated compared to the A375(DRO) SCR subline in all treatment conditions. Columns, mean; bars, SEM.
